- Home
- GF vs IKT Comparison
GF vs IKT Comparison
Compare GF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- IKT
- Stock Information
- Founded
- GF 1990
- IKT 2008
- Country
- GF Germany
- IKT United States
- Employees
- GF N/A
- IKT N/A
- Industry
- GF Investment Managers
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- IKT Health Care
- Exchange
- GF Nasdaq
- IKT Nasdaq
- Market Cap
- GF 167.2M
- IKT 167.2M
- IPO Year
- GF N/A
- IKT 2020
- Fundamental
- Price
- GF $9.76
- IKT $1.98
- Analyst Decision
- GF
- IKT Buy
- Analyst Count
- GF 0
- IKT 2
- Target Price
- GF N/A
- IKT $8.00
- AVG Volume (30 Days)
- GF 28.1K
- IKT 130.7K
- Earning Date
- GF 01-01-0001
- IKT 05-14-2025
- Dividend Yield
- GF 0.82%
- IKT N/A
- EPS Growth
- GF N/A
- IKT N/A
- EPS
- GF N/A
- IKT N/A
- Revenue
- GF N/A
- IKT N/A
- Revenue This Year
- GF N/A
- IKT N/A
- Revenue Next Year
- GF N/A
- IKT N/A
- P/E Ratio
- GF N/A
- IKT N/A
- Revenue Growth
- GF N/A
- IKT N/A
- 52 Week Low
- GF $7.38
- IKT $1.12
- 52 Week High
- GF $9.41
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- GF 48.20
- IKT 36.36
- Support Level
- GF $9.71
- IKT $2.08
- Resistance Level
- GF $9.86
- IKT $2.27
- Average True Range (ATR)
- GF 0.13
- IKT 0.17
- MACD
- GF -0.12
- IKT -0.02
- Stochastic Oscillator
- GF 5.32
- IKT 6.92
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.